These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 23154039

  • 1. A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3.
    Lichtman MA.
    Blood Cells Mol Dis; 2013 Feb; 50(2):119-30. PubMed ID: 23154039
    [Abstract] [Full Text] [Related]

  • 2. [Progress in the field of hematology in the last 100 years: Medical history of acute leukemia].
    Ono R.
    Nihon Naika Gakkai Zasshi; 2002 Jul 10; 91(7):2084-9. PubMed ID: 12187682
    [No Abstract] [Full Text] [Related]

  • 3. [The therapeutic results in acute myeloid leukemias in elderly patients].
    Parovichnikova EN, Savchenko VG, Isaev VG, Tikhonova LIu, Sarycheva TG, Kulikov SM.
    Ter Arkh; 1992 Jul 10; 64(8):87-9. PubMed ID: 1440406
    [No Abstract] [Full Text] [Related]

  • 4. [Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
    Taguchi H, Kubonishi I, Takehara N, Uemura Y, Iwahara Y, Eguchi T, Miyagi T, Sugito S, Muneishi H, Tanaka Y.
    Gan To Kagaku Ryoho; 1992 Aug 10; 19(9):1309-14. PubMed ID: 1503485
    [Abstract] [Full Text] [Related]

  • 5. Therapy of acute myelogenous leukemia: results of combination chemotherapy with cytarabine, daunorubicin and 6-mercaptopurine.
    Ko WS, Chen LM, Hwang SH, Chao TY, Wang CC, Kao WY, Lee WC, Hwang WS.
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 Sep 10; 48(3):185-9. PubMed ID: 1657335
    [Abstract] [Full Text] [Related]

  • 6. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
    Vogler WR, Velez-Garcia E, Omura G, Raney M.
    Semin Oncol; 1989 Feb 10; 16(1 Suppl 2):21-4. PubMed ID: 2648581
    [No Abstract] [Full Text] [Related]

  • 7. Neurological complications during treatment of childhood cancer: mind Wernicke encephalopathy.
    La Spina M, Catania R, Lo Nigro L, De Grandi C, Palmucci S, Di Cataldo A.
    Pediatr Hematol Oncol; 2010 May 10; 27(4):320-3. PubMed ID: 20426524
    [No Abstract] [Full Text] [Related]

  • 8. Long-term results of AIEOP-8805 protocol for acute B-cell lymphoblastic leukemia of childhood.
    Pillon M, Aricò M, Basso G, Locatelli F, Citterio M, Micalizzi C, Testi AM, Barisone E, Nardi M, Lombardi A, Rondelli R, Rosolen A, NHL-Committee of the Italian Association of Pediatric Hematology, Oncology.
    Pediatr Blood Cancer; 2011 Apr 10; 56(4):544-50. PubMed ID: 21298738
    [Abstract] [Full Text] [Related]

  • 9. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000.
    Schrappe M, Möricke A, Reiter A, Henze G, Welte K, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Gruhn B, Niemeyer C, Kremens B, Niggli F, Debatin KM, Ratei R, Stanulla M, Beier R, Cario G, Schrauder A, Zimmermann M.
    Klin Padiatr; 2013 May 10; 225 Suppl 1():S62-72. PubMed ID: 23700060
    [Abstract] [Full Text] [Related]

  • 10. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A, Rinaldi CR, Palmieri S, Cantore N, Mele G, Mettivier V, Miraglia E, Mastrullo L, Grimaldi F, Luciano L, Guerriero A, Rotoli B, Ferrara F.
    Ann Hematol; 2009 Feb 10; 88(2):151-8. PubMed ID: 18709502
    [Abstract] [Full Text] [Related]

  • 11. Important milestones in acute leukemia in 2013.
    Rowe JM.
    Best Pract Res Clin Haematol; 2013 Sep 10; 26(3):241-4. PubMed ID: 24309524
    [Abstract] [Full Text] [Related]

  • 12. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, Galaverna F, Miglino M, Di Grazia C, Ballerini F, Marani C, Pastori G, Mitscheunig L, Cruciani F, Lovera D, Varaldo R, Ghiggi C, Lemoli RM, Bacigalupo A, Gobbi M.
    Ann Hematol; 2014 Dec 10; 93(12):2011-8. PubMed ID: 24989345
    [Abstract] [Full Text] [Related]

  • 13. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
    Reinhardt D, Hempel G, Fleischhack G, Schulz A, Boos J, Creutzig U.
    Klin Padiatr; 2002 Dec 10; 214(4):188-94. PubMed ID: 12165900
    [Abstract] [Full Text] [Related]

  • 14. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
    Dobashi N, Usui N, Yano S, Yahagi Y, Takei Y, Sugiyama K, Takahara S, Ogasawara Y, Yamaguchi Y, Saito T, Yokoyama H, Aiba K.
    Jpn J Clin Oncol; 2011 Jun 10; 41(6):820-4. PubMed ID: 21415001
    [Abstract] [Full Text] [Related]

  • 15. [Cancer curable by chemotherapy: acute myelogenous leukemia].
    Ohno R, Tanimoto M, Morishita Y, Morishima Y, Saito H, Yokomaku S, Nagai T, Kodera Y, Minami S.
    Gan To Kagaku Ryoho; 1989 Apr 10; 16(4 Pt 2-2):1329-34. PubMed ID: 2730046
    [Abstract] [Full Text] [Related]

  • 16. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E, Fiere D, Treille-Ritouet D, Adeleine P, Guyotat D, Sebban C, Vuvan H, Viala JJ.
    Cancer Treat Rep; 1987 Jun 10; 71(6):571-4. PubMed ID: 3555788
    [Abstract] [Full Text] [Related]

  • 17. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L, Qu Q, Jiao W, Zhang Y, Li X, Ding C, Wu D.
    Leuk Res; 2015 Aug 10; 39(8):805-11. PubMed ID: 26021434
    [Abstract] [Full Text] [Related]

  • 18. Treatment of acute non-lymphocytic leukemia with alternating non-cross resistant chemotherapy.
    Kyo T, Dohy H.
    Nihon Ketsueki Gakkai Zasshi; 1988 Dec 10; 51(8):1641-52. PubMed ID: 3247827
    [No Abstract] [Full Text] [Related]

  • 19. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM, Ribera JM, Xicoy B, Morgades M, Oriol A, Tormo M, del Potro E, Debén G, Abella E, Bethencourt C, Ortín X, Brunet S, Ortega-Rivas F, Novo A, López R, Hernández-Rivas JM, Sanz MA, Feliu E, PETHEMA Group.
    Eur J Haematol; 2007 Feb 10; 78(2):102-10. PubMed ID: 17087744
    [Abstract] [Full Text] [Related]

  • 20. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
    Wiernik PH, Case DC, Periman PO, Arlin ZA, Weitberg AB, Ritch PS, Todd MB.
    Semin Oncol; 1989 Feb 10; 16(1 Suppl 2):25-9. PubMed ID: 2928807
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.